Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease

Launched by LEXEO THERAPEUTICS · May 27, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at the long-term safety of a gene therapy called LX1001 for people with a specific type of Alzheimer's disease, known as APOE4 homozygote Alzheimer's. The study is following participants who previously received this treatment to see how it affects their health over time. Researchers will also measure various markers in the brain and spinal fluid to understand how the therapy works and whether it helps improve brain function and signs of Alzheimer's.

To join this study, participants must have already received LX1001 in a previous trial. It's important for potential participants to be in good health overall, as certain medical conditions might exclude them from joining. During the study, participants can expect regular check-ups and tests to monitor their health and the effects of the treatment. This research is important for understanding how gene therapy might help manage Alzheimer’s disease in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants who received LX1001 in study LX1001-01
• Exclusion Criteria:
• • Participants with any clinically significant medical condition that, in the opinion of the investigator, would pose a risk to participant safety
• • Participants who agree not to post their personal medical data in relation to this study or any study information online, including social media sites, until all participants have completed all LX1001 clinical studies, including long-term follow-up.